NCT02326974 2026-04-17
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
Dana-Farber Cancer Institute
Medical College of Wisconsin
Stanford University
Memorial Sloan Kettering Cancer Center
Ohio State University Comprehensive Cancer Center
Institut Cancerologie de l'Ouest
Haukeland University Hospital
Dana-Farber Cancer Institute